EP1408934A2 - Composition pharmaceutique de prophylaxie et de traitement de troubles du metabolisme calcique - Google Patents

Composition pharmaceutique de prophylaxie et de traitement de troubles du metabolisme calcique

Info

Publication number
EP1408934A2
EP1408934A2 EP02760933A EP02760933A EP1408934A2 EP 1408934 A2 EP1408934 A2 EP 1408934A2 EP 02760933 A EP02760933 A EP 02760933A EP 02760933 A EP02760933 A EP 02760933A EP 1408934 A2 EP1408934 A2 EP 1408934A2
Authority
EP
European Patent Office
Prior art keywords
active ingredient
glyceryl palmitostearate
preparation
clodronate
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02760933A
Other languages
German (de)
English (en)
Inventor
Lelia-Georgeta Lazar
Tincuta Dinu
Cornelia Stancu
Irinel Badea
Maria Rotaru
Veronica Draghici
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis SRL
Original Assignee
Sc Sindan Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sc Sindan Srl filed Critical Sc Sindan Srl
Publication of EP1408934A2 publication Critical patent/EP1408934A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Definitions

  • the object of the present invention is to provide a pharmaceutical composition containing disodium clodronate, tetrahydrate, for oral use, filled in hard gelatin capsules, using an excipient from the group of triglycerides, for example atomized glyceryl palmitostearate, with double role, of lubricant and binder.
  • the preparation is used for the treatment and prophylaxis of calcium metabolism disorders, as bone resorbtion, hypercalcemia and osteoporosis and contains as active ingredient a bisphosphonic acid derivative, for example disodium clodronate.
  • the active ingredient disodium clodronate tetrahydrate, granulated by fluid bed wet granulation method, is released from the preparation in a proportion of at least 75% during the first 5 minutes and at least 95% in 30 minutes.
  • Clodronate (disodium salt of dichlormethylen bisphosphonic acid, tetrahydrate) is administered by the oral route, as tablets or hard gelatin capsules, being used for the treatment and prophylaxis of calcium metabolism disorders, like bone resorbtion, hypercalcemia and osteoporosis.
  • the active ingredient is a powder with a big bulk volume and inadequate flowing.
  • classical methods were used: wet granulation and dry granulation.
  • Wet granulation consists in agglomeration of particles using a solvent or a binder solution, in order to obtain a high-density powder mixture.
  • Dry granulation is performed by compaction of the powder under high pressure.
  • EP 275 468 describes a preparation which contains 80 to 90% clodronate, 2 to 10% diluents and 1 to 10% lubricants and a method to obtain the preparation by mixing the components and wet granulation using an aqueous binder solution. The granulate is then dried, lubricants are added 1 to 5% and mixed and the mixture is compressed into tablets or it is used for filling hard gelatin capsules. Over 90% of the active ingredient are released from the preparation after 30 minutes.
  • WO 95/13054 describes a method of crystallization of disodium clodronate tetrahydrate and dry granulation by compaction under controlled conditions, which do not affect the tetrahydrate structure. This processing method allows to obtain granulate with adequate flowing (rheological) properties and which needs small amounts of lubricants.
  • WO 99/15155 discloses that by using an excipient named silicated microcrystalline cellulose in preparations containing clodronate, obtained by wet or dry granulation, powders with adequate characteristics are obtained, in terms of flowing and compressibility, and tablets have a good mechanical resistance and, especially, a low friability.
  • excipients are used for preparations with clodronate intended for oral use, having the following functions: diluents (weight compensators) such as lactose or starch derivatives, lubricants such as stearic acid and its salts of calcium or magnesium, talc, starch, sodium lauryl sulphate or combinations of two or more lubricants.
  • diluents weight compensators
  • lubricants such as stearic acid and its salts of calcium or magnesium
  • talc talc
  • starch sodium lauryl sulphate or combinations of two or more lubricants.
  • enteric-coated pharmaceutical preparations may be manufactured (allowing the release of the active ingredient at enteric level), method described in WO 93/21907 or several excipients, like sodium lauryl sulphate or microcrystalline cellulose may be used.
  • excipients like sodium lauryl sulphate or microcrystalline cellulose
  • WO 94/26310 the use of microcrystalline cellulose as excipient leads to clodronate tablets with better absorption.
  • glyceryl tribehenate as lubricant (it is obtained from the esterification of glycerol with behenic acid, fatty acid with 22 carbon atoms).
  • clodronate hard gelatin capsules using an excipient from the group of triglycerides, namely glyceryl palmitostearate, which has a double role, of lubricant and binder and which replaces usual excipients like talc or magnesium stearate, because they can have a negative effect on the release of the active ingredient from the preparation.
  • the preparation contains disodium clodronate tetrahydrate as active ingredient, which is granulated using the method of wet granulation in fluid air bed and which is released in a proportion of at least 75% during first 5 minutes and at least 95% in 30 minutes (Fig.l).
  • the atomized glyceryl palmitostearate is compatible with hard gelatin capsules and it is composed from uniform spherical particles, therefore having very good lubricant properties as compared to classical lubricants, no matter the type of blender, the mixing time or the nature of other excipients.
  • the atomized glyceryl palmitostearate has also binding properties, allowing a better compressibility of the powder mix in the dosing disk of the capsule filling machine, having effects on the number of excipients used in the formulation and, consequently, on the weight of the dosage unit.
  • the atomized glyceryl palmitostearate is used for preparing hard gelatin capsules containing disodium clodronate because it allows the reduction of the quantity of excipients required for a powder mix with good flowing properties.
  • Using the atomized glyceryl palmitostearate we obtain a better uniformity of the capsule filling content, the uniformity of the dosage of active ingredient per unit being very important because of the low digestive absorption of the clodronate, which is also negatively affected by food.
  • the atomized glyceryl palmitostearate does not delay the release of the active ingredient from the preparation, because it has no hydrophobic properties like classical lubricants (ex: talc, magnesium stearate)
  • the atomized glyceryl palmitostearate (for example PRECIROL® ATO 5, registered trade name of GATTEFOSSE - FRANCE product) is used in hard gelatin capsules formulations in a percentage of 1- 3 %. It is a mixture composed of mono-, di- and tri- glycerides, the diester fraction being the most important. It is obtained by esterification of glycerol and palmitostearic acid ( C16 - C18 fatty acid). The product is then spray atomized. Raw materials are strictly of vegetal origin and the process for obtaining the product does not use any catalysts.
  • a capsule filling machine which works on the principle of powder compression into a dosing disk.
  • the dosing disk contains five stations for compression of the powder mix with the help of a set of punches.
  • the obtained powder plug is then transferred into the body of the capsule.
  • the powder material should have binding properties, so as to form the plug of material into the dosing disk which is then transferred into the body of the capsule without losses of material.
  • the disodium clodronate, tetrahydrate is processed by wet granulation, which is widely used in pharmaceutical industry because of its technological advantages as compared to dry granulation.
  • wet granulation materials with good wetting properties are obtained, having an adequate size and shape for a good flowing.
  • the shape of the particles obtained by dry granulation is irregular or plane and a bigger quantity of lubricants is necessary for a good flowing.
  • Fluidized bed wet granulation of disodium clodronate, tetrahydrate is performed without binding agents, using as wetting liquid a mix of water and alcohol 1:1 in volumes.
  • the mixture of solvents used for agglomeration of the particles partially dissolves the active ingredient.
  • this active ingredient crystallizes, acting like a binder.
  • the size of the obtained particles depends on the drying speed: the lower the speed, the larger the size of the particles. Care must be taken not to obtain too big particles by re-crystallizing, because they can reduce the dissolution rate.
  • the fluidized bed wet granulation has the advantage of a short drying time, in comparison with the classical wet granulation methods. Also, by adding the wetting liquid by spray the risk of over-wetting is avoided.
  • the disodium clodronate tetrahydrate granulated by fluidized bed method is a mix of isolated and structured aggregates, with a water content of 18-20%, corresponding to the tetrahydate and the remaining water traces from the granulation process.
  • the granulate has good flowing properties, so that only a small quantity of lubricants is necessary.
  • Monohydrate lactose is used to compensate the capsule filling weight.
  • Monohydrate lactose is a diluting agent widely used in oral preparation because it is water soluble and not hygroscopic.
  • the type 200 mesh was chosen due to its good flowing properties, so the granulometric distribution of the powder is in a narrow range, thus avoiding the segregation during the filling process.
  • Colloidal silicon dioxide is used as gliding agent.
  • the pharmaceutical preparation contains 92,6% disodium clodronate tetrahydrate, 3,9 - 6,3 % monohydrate lactose, 0,1 - 0,5 % silicon dioxide and 1 - 3 % atomized glyceryl palmitostearate, relative to the total weight.
  • a fully automatic and reproducible process is used to obtain the preparation and the powder mix is obtained with a fine and uniform granulometric distribution and adequate flowing properties for capsule filling.
  • the powder is not sticking to the punches and uniform filled capsules are obtained, with a RSD of the filling mass less then 1% (table 1).
  • the following example illustrates the present invention, without limiting it:
  • the method of obtaining the powder mix for capsule filling is the following: Disodium clodronate tetrahydrate is wet granulated by fluid bed method, using a mix of water and alcohol as wetting liquid. The granulate is dried at 35 - 40°C until a water content of 18 - 20% is reached. The dried and homogeneous granulate is blended with other excipients: lactose, silicon dioxide and atomized glyceryl palmitostearate and the powder mix is used for hard gelatin capsule filling.
  • Capsules prepared according to the composition and method of preparation described above have been tested for their physical-chemical parameters: filling mass per capsule, dosage of the active ingredient in the capsule and dissolution of the active ingredient. The results are presented in Table 1.
  • the active ingredient of the present invention is water soluble at room temperature (2,5 g/10 ml).
  • the active ingredient passes into the acid form, with lower absorption and reduced bioavailability.
  • the disodium clodronate respectively clodronic acid, cannot pass through the lipidic barriers, which leeds to an extremely low bioavailability.
  • the dissolution test parameters were selected according to the official monograph of Etidronate Dissodium Tablets (USP XXIII, pg. 647), as the disodium clodronate doesn't exist in any official pharmacopeia. For this reason the dissolution test parameters are: Apparatus I-basket: 100 m; Medium : distilled water, 1000 mL; Time: 30 minutes.
  • the pharmaceutical prepared according to the present invention has a good dissolution.
  • the active ingredient is released in a proportion of at least 75% in first 5 minutes and at least 95% in 30 minutes (Fig.l).
  • an excipient with double role can be used, as lubricant and binder, which allows the release of the active ingredient from the preparation at least 75% in first 5 minutes and at least 95% in 30 minutes.
  • the active ingredient is a derivate of bisphosphonic acid, and in this formulation it is proved to be physico-chemically stable also in accelerated conditions (40° ⁇ 2°C / 75% RH ⁇ 5% , 6 months) and on long term (25° ⁇ 2°C / 60% RH ⁇ 5%), at least one year (the study is in progress).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique pour administration orale, sous forme de capsules de gélatine dure, qui contient un excipient de la classe des triglycérides, par exemple du palmitostéarate de glycéryle atomisé, possédant le double rôle, de lubrifiant et de liant. Cette composition est utilisée dans le traitement et la prophylaxie de troubles du métabolisme calcique, tels que la résorption osseuse, l'hypercalcémie et l'ostéoporose et contient en tant que principe actif un dérivé d'acide biphosphonique, par exemple du clodronate de disodium. Le principe actif, le tétrahydrate de clodronate de disodium, granulé au moyen d'un procédé à lit fluidisé, et libéré de la préparation dans une proportion d'au moins 75 % pendant les 5 premières minutes et d'au moins 95 % en 30 minutes.
EP02760933A 2001-07-04 2002-07-02 Composition pharmaceutique de prophylaxie et de traitement de troubles du metabolisme calcique Withdrawn EP1408934A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ROA200100780A RO121891B1 (ro) 2001-07-04 2001-07-04 Compoziţie farmaceutică pentru profilaxia şi tratamentul dereglărilor metabolismului calciului şi procedeu de preparare
RO200100780 2001-07-04
PCT/RO2002/000017 WO2003004008A2 (fr) 2001-07-04 2002-07-02 Composition pharmaceutique de prophylaxie et de traitement de troubles du metabolisme calcique

Publications (1)

Publication Number Publication Date
EP1408934A2 true EP1408934A2 (fr) 2004-04-21

Family

ID=20129443

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02760933A Withdrawn EP1408934A2 (fr) 2001-07-04 2002-07-02 Composition pharmaceutique de prophylaxie et de traitement de troubles du metabolisme calcique

Country Status (4)

Country Link
EP (1) EP1408934A2 (fr)
AU (1) AU2002326251A1 (fr)
RO (1) RO121891B1 (fr)
WO (1) WO2003004008A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275468A1 (fr) * 1986-12-20 1988-07-27 Roche Diagnostics GmbH Compositions pharmaceutiques contenant du clodronate et leur procédé de préparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94926C (fi) 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275468A1 (fr) * 1986-12-20 1988-07-27 Roche Diagnostics GmbH Compositions pharmaceutiques contenant du clodronate et leur procédé de préparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENNARO A R: "Remington: THe Science and Practice of Pharmacy", 1995, MACK PUBLISHING COMPANY, EASTON, PENNSYLVANIA (US) *
See also references of WO03004008A3 *

Also Published As

Publication number Publication date
WO2003004008A2 (fr) 2003-01-16
RO121891B1 (ro) 2008-07-30
WO2003004008A3 (fr) 2003-05-01
AU2002326251A1 (en) 2003-01-21

Similar Documents

Publication Publication Date Title
EP0097523B1 (fr) Compositions à libération contrôlée et prolongée
CA2301185C (fr) Preparation pharmaceutique comprenant du clodronate en tant que principe actif et de la cellulose microcristalline silicifiee en tant qu'excipient
EP1056445B1 (fr) Forme galenique s'administrant par voie orale, a liberation immediate et prolongee, et comprenant un agent favorisant l'absorption et utilisation de cet agent
ES2652415T3 (es) Preparación para aplicación transnasal
EP2560612B1 (fr) Procédé de préparation de compositions pharmaceutiques destinées à une administration orale, comprenant un ou plusieurs principes actifs, et compositions les comprenant
WO2002011701A1 (fr) Composition pharmaceutique a liberation controlee
AU748396B2 (en) Composition
KR100367302B1 (ko) 소수성활성물질과발포제를포함하는제약학적조성물과이의준비공정
US6558703B1 (en) Porous hydroxyapatite particles as carriers for drug substances
EP1874357A1 (fr) Formes de dosage de produits pharmaceutiques comprenant une phase lipidique
WO2011120530A1 (fr) Comprimés poreux en tant que véhicules pour formulations liquides
JP2006517929A (ja) 溶融アグロメレーションを用いてアグロメレートを製造する方法
BG65713B1 (bg) Фармацевтичен състав с контролирано освобождаване, съдържащ трамадол хидрохлорид, и метод за неговото получаване
EP1952805B1 (fr) Comprimé contenant des phospholipides hydrogénés
US20100021393A1 (en) Pharmaceutical Compositions Comprising Effervescent Agents and Fenofibrate
EP1408934A2 (fr) Composition pharmaceutique de prophylaxie et de traitement de troubles du metabolisme calcique
JP4475693B2 (ja) アセトアミノフェン含有発泡組成物
TWI597063B (zh) 藥物組成物及其製備方法
CN104870018A (zh) 具有改善的活性物质的释放作为药物制剂中载体的碱式碳酸镁
US20050215455A1 (en) Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them
WO1999020277A1 (fr) Composition medicamenteuse a dissolution rapide
WO2025226228A1 (fr) Nouvelle formulation pour comprimé de palbociclib
HU191102B (en) Process for producing pharmaceutical compositions of regulated dissolution of the active agents containing water-soluble inorganic pharmacons
HK1125023A (en) Pharmaceutical dosage forms comprising a lipid phase
MXPA00008203A (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK SI

17P Request for examination filed

Effective date: 20040504

17Q First examination report despatched

Effective date: 20051230

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ACTAVIS SRL

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAC Information related to communication of intention to grant a patent modified

Free format text: ORIGINAL CODE: EPIDOSCIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091105